| # | % | |||||
|---|---|---|---|---|---|---|
| 1 | AVEO PHARMACEUTICALS INC | 1,013,616 | 598,000 | 0.24% | ||
| 2 | ABBVIE INC | 10,000 | 651,000 | 0.26% | ||
| 3 | ADVAXIS INC COM NEW | 339,180 | 2,771,000 | 1.10% | ||
| 4 | VIVUS INC | 2,573,943 | 2,882,000 | 1.14% | ||
| 5 | APRICUS BIOSCIENCES INC | 1,447,906 | 3,055,000 | 1.21% | ||
| 6 | INTRA-CELLULAR THERAPIES INC | 360,000 | 5,850,000 | 2.31% | ||
| 7 | BIOVERATIV INC | 155,000 | 8,441,000 | 3.34% | ||
| 8 | NOVELION THERAPEUTICS INC | 1,025,000 | 11,008,000 | 4.35% | ||
| 9 | INNOVIVA INC COM | 3,425,000 | 47,367,000 | 18.72% | ||
| 10 | BIOGEN INC | 310,000 | 84,760,000 | 33.49% | ||
| 11 | MEDICINES CO | 1,752,000 | 85,672,000 | 33.86% |
Portfolio data is normalized using SEC Form 13F filings, including the Original 13F-HR (0001140361-17-020718, filed 2017.05.15).
From 2023-01-03 onward, the SEC requires values to be reported in nearest dollars. Earlier filings reported values in thousands; therefore, positions shown as $0 in older filings may represent actual values between $0–$999.
